Elias Anaissie

The molecular classification of multiple myeloma.

John Crowley, Simona Colla, Bart Barlogie, 2006, Blood.

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

Bart Barlogie, Louis Fink, Joth Jacobson, 2004, British journal of haematology.

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

John Crowley, Pingping Qu, Bart Barlogie, 2011, Blood.

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2

David R Williams, Bart Barlogie, O. Stephens, 2010, Proceedings of the National Academy of Sciences.

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

John Crowley, Bart Barlogie, Johanna Hardin, 2002, Blood.

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.

John Crowley, Erik Rasmussen, Bart Barlogie, 2006, Blood.

Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

John Crowley, Erik Rasmussen, Bart Barlogie, 2006, The New England journal of medicine.